In a game-changing collaboration, France's Pierre Fabre Laboratories and China's Sinopharm have teamed up to ramp up localized production of cutting-edge cancer treatments. The deal, signed this week, marks the French company's first major move in the Chinese mainland since appointing new CEO Marie-Andrée Gamache earlier this year.
🔬 Why it matters: With China's 15th Five-Year Plan (2026-2030) launching next year, international pharma players are racing to align with Beijing's healthcare modernization goals. Gamache told CGTN: "We see China not just as a market, but as a strategic partner in fighting global health challenges."
🌏 The big picture: This partnership comes as multinationals increasingly localize R&D and manufacturing in China. Analysts predict the move will give Pierre Fabre better access to Asia's largest healthcare market while supporting China's push for self-reliance in critical medicines.
